J. Mark Cooper
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
J. Mark Cooper has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Anthony Henry Vernon Schapira
Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK
3 shared publications - Andrew Matthew Blamire
Newcastle University Translational and Clinical Research Institute (NUTCRI) Newcastle University Newcastle upon Tyne UK
1 shared publication Bheeshma Rajagopalan
1 shared publicationChristopher Turner
1 shared publication- David Neil Manners
Functional MR Unit, Policlinico S. Orsola - Malpighi, Via Massarenti 9, 40138, Bologna, Italy; Department of Biomedical and NeuroMotor Sciences, University of Bologna, Via U. Foscolo 7, 40123, Bologna, Italy
1 shared publication J. L. Bradley
Department of Clinical Neuroscience, Royal Free and University College Medical School, University College London, Rowland Hill Street, London NW3 2PF, United Kingdom
1 shared publication
Latest Publications
- 1 April 2005
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 62 (4) , 621-626
Antioxidant Treatment of Patients With Friedreich Ataxia
Research from JAMA Neurology — Antioxidant Treatment of Patients With Friedreich Ataxia — Four-Year Follow-up
- 1 April 2005
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 62 (4) , 621-626
Antioxidant Treatment of Patients With Friedreich Ataxia
Research from JAMA Neurology — Antioxidant Treatment of Patients With Friedreich Ataxia — Four-Year Follow-up
- 1 March 2004
- Published by Springer Nature in Neurochemical Research
- Vol. 29 (3) , 561-567
Role of Oxidative Damage in Friedreich's Ataxia
Plasma malondialdehyde (MDA) levels were raised in Friedreich's ataxia (FRDA) patients. These levels correlated with increasing age and disease duration, suggesting lipid peroxidation increased with...
- 1 March 2004
- Published by Springer Nature in Neurochemical Research
- Vol. 29 (3) , 561-567
Role of Oxidative Damage in Friedreich's Ataxia
Plasma malondialdehyde (MDA) levels were raised in Friedreich's ataxia (FRDA) patients. These levels correlated with increasing age and disease duration, suggesting lipid peroxidation increased with...
- 1 January 2003
- Published by Wiley in BioFactors
- Vol. 18 (1-4) , 163-171
Friedreich's Ataxia: Disease mechanisms, antioxidant and Coenzyme Q10therapy
Mitochondria clearly play a central role in the pathogenesis of Friedreich's Ataxia. The most common genetic abnormality results in the deficiency of the protein frataxin, which is targeted to the mitochondrion. Research since this discovery has indicated that mitochondrial respiratory chain dysfunction, mitochondrial iron accumulation and oxidative damage are important components of the disease mechanism. While the role of frataxin is not known, evidence is currently pointing to a role in either mitochondrial iron handling or iron sulphur centre synthesis. These advances in our understanding of the disease mechanisms are enabling therapeutic avenues to be explored, in particular the use of established drugs such as antioxidants and enhancers of respiratory chain function. Vitamin E therapy has been shown to be beneficial in patients with ataxia with vitamin E deficiency, and CoQ10therapy was effective in some patients with ataxia associated with CoQ10deficiency. A combined therapy involving long term treatment with high doses of vitamin E and coenzyme Q10has jointly targeted two of the major features of Friedreich's Ataxia; decreased mitochondrial respiratory chain function and increased oxidative stress. This therapy clearly showed a rapid and sustained increase in the energy generated by the FRDA heart muscle, nearly returning to normal levels. The improvements in skeletal muscle energy generation parallel those of the heart but to a lower level. While this therapy appeared to slow the predicted progression of some clinical symptoms a larger placebo controlled study is required to confirm these observations. Other antioxidant strategies have involved the use of Idebenone, selenium and N acetyl cysteine but only the use of Idebenone has involved structured trials with relatively large patient numbers. Idebenone clearly had an impact upon the cardiac hypertrophy in the majority of patients, although there have not been any other significant benefits reported to date.
- 1 January 2003
- Published by Wiley in BioFactors
- Vol. 18 (1-4) , 163-171
Friedreich's Ataxia: Disease mechanisms, antioxidant and Coenzyme Q10therapy
Mitochondria clearly play a central role in the pathogenesis of Friedreich's Ataxia. The most common genetic abnormality results in the deficiency of the protein frataxin, which is targeted to the mitochondrion. Research since this discovery has indicated that mitochondrial respiratory chain dysfunction, mitochondrial iron accumulation and oxidative damage are important components of the disease mechanism. While the role of frataxin is not known, evidence is currently pointing to a role in either mitochondrial iron handling or iron sulphur centre synthesis. These advances in our understanding of the disease mechanisms are enabling therapeutic avenues to be explored, in particular the use of established drugs such as antioxidants and enhancers of respiratory chain function. Vitamin E therapy has been shown to be beneficial in patients with ataxia with vitamin E deficiency, and CoQ10therapy was effective in some patients with ataxia associated with CoQ10deficiency. A combined therapy involving long term treatment with high doses of vitamin E and coenzyme Q10has jointly targeted two of the major features of Friedreich's Ataxia; decreased mitochondrial respiratory chain function and increased oxidative stress. This therapy clearly showed a rapid and sustained increase in the energy generated by the FRDA heart muscle, nearly returning to normal levels. The improvements in skeletal muscle energy generation parallel those of the heart but to a lower level. While this therapy appeared to slow the predicted progression of some clinical symptoms a larger placebo controlled study is required to confirm these observations. Other antioxidant strategies have involved the use of Idebenone, selenium and N acetyl cysteine but only the use of Idebenone has involved structured trials with relatively large patient numbers. Idebenone clearly had an impact upon the cardiac hypertrophy in the majority of patients, although there have not been any other significant benefits reported to date.